Search by Drug Name or NDC

    NDC 00078-0331-84 Simulect 20 mg/5mL Details

    Simulect 20 mg/5mL

    Simulect is a INTRAVENOUS INJECTION, POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is BASILIXIMAB.

    Product Information

    NDC 00078-0331
    Product ID 0078-0331_d25af03e-66f5-4184-a769-cbe62de929f9
    Associated GPIs 99405015002120
    GCN Sequence Number 039803
    GCN Sequence Number Description basiliximab VIAL 20 MG INTRAVEN
    HIC3 Z2M
    HIC3 Description IMMUNOSUPP - MONOCLONAL AB INHIBITING T LYMPH FXN
    GCN 64731
    HICL Sequence Number 018390
    HICL Sequence Number Description BASILIXIMAB
    Brand/Generic Brand
    Proprietary Name Simulect
    Proprietary Name Suffix n/a
    Non-Proprietary Name basiliximab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, POWDER, FOR SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 20
    Active Ingredient Units mg/5mL
    Substance Name BASILIXIMAB
    Labeler Name Novartis Pharmaceuticals Corporation
    Pharmaceutical Class Interleukin 2 Receptor Antagonists [MoA], Interleukin 2 Receptor-directed Antibody Interactions [MoA], Interleukin-2 Receptor Blocking Antibody [EPC]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA103764
    Listing Certified Through 2024-12-31

    Package

    NDC 00078-0331-84 (00078033184)

    NDC Package Code 0078-0331-84
    Billing NDC 00078033184
    Package 1 VIAL, SINGLE-USE in 1 CARTON (0078-0331-84) / 5 mL in 1 VIAL, SINGLE-USE
    Marketing Start Date 1998-05-12
    NDC Exclude Flag N
    Pricing Information N/A